15.56
-0.19 (-1.21%)
| Penutupan Terdahulu | 15.75 |
| Buka | 15.73 |
| Jumlah Dagangan | 162,588 |
| Purata Dagangan (3B) | 575,537 |
| Modal Pasaran | 5,646,988,800 |
| Harga / Pendapatan (P/E Ke hadapan) | 13.42 |
| Harga / Jualan (P/S) | 0.900 |
| Harga / Buku (P/B) | 0.670 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 19 Feb 2025 |
| Margin Keuntungan | -6.62% |
| Margin Operasi (TTM) | 6.72% |
| EPS Cair (TTM) | -0.900 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 9.10% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 75.43% |
| Nisbah Semasa (MRQ) | 1.60 |
| Aliran Tunai Operasi (OCF TTM) | 232.00 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 188.38 M |
| Pulangan Atas Aset (ROA TTM) | 0.96% |
| Pulangan Atas Ekuiti (ROE TTM) | -4.53% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Medical Instruments & Supplies (US) | Menurun | Bercampur |
| Medical Instruments & Supplies (Global) | Menurun | Menurun | |
| Stok | Bausch + Lomb Corporation | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | -3.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -1.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -1.0 |
| Purata | -0.75 |
|
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space. |
|
| Sektor | Healthcare |
| Industri | Medical Instruments & Supplies |
| Gaya Pelaburan | Mid Core |
| % Dimiliki oleh Orang Dalam | 88.18% |
| % Dimiliki oleh Institusi | 10.25% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Maple Rock Capital Partners Inc. | 31 Dec 2024 | 3,171,053 |
| Goldentree Asset Management Lp | 31 Dec 2024 | 1,732,197 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 17.00 (RBC Capital, 9.25%) | Beli |
| Median | 15.00 (-3.60%) | |
| Rendah | 12.00 (Morgan Stanley, -22.88%) | Pegang |
| 12.00 (Wells Fargo, -22.88%) | Pegang | |
| Purata | 14.21 (-8.68%) | |
| Jumlah | 3 Beli, 4 Pegang | |
| Harga Purata @ Panggilan | 11.75 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Morgan Stanley | 06 May 2025 | 12.00 (-22.88%) | Pegang | 10.90 |
| HC Wainwright & Co. | 02 May 2025 | 15.00 (-3.60%) | Beli | 11.50 |
| Citigroup | 01 May 2025 | 13.00 (-16.45%) | Pegang | 11.59 |
| Evercore ISI Group | 01 May 2025 | 15.50 (-0.39%) | Beli | 11.59 |
| Wells Fargo | 01 May 2025 | 12.00 (-22.88%) | Pegang | 11.59 |
| 28 Mar 2025 | 15.00 (-3.60%) | Pegang | 14.13 | |
| RBC Capital | 04 Apr 2025 | 17.00 (9.25%) | Beli | 12.11 |
| Stifel | 03 Apr 2025 | 15.00 (-3.60%) | Pegang | 12.99 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |